Dyadic International (NASDAQ:DYAI) Stock Passes Below Fifty Day Moving Average – Should You Sell?

Posted by Brian Himes on Sep 16th, 2026

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.88 and traded as low as $0.3527. Dyadic International shares last traded at $0.4244, with a volume of 490,904 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Check Out Our Latest Research Report on Dyadic International

Dyadic International Trading Down 5.9%

The company has a debt-to-equity ratio of 4.08, a current ratio of 1.65 and a quick ratio of 1.65. The firm has a market cap of $14.67 million, a price-to-earnings ratio of -1.75 and a beta of 0.96. The firm’s fifty day moving average is $0.87 and its 200-day moving average is $0.82.

Dyadic International (NASDAQ:DYAI – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%.The business had revenue of $0.96 million during the quarter, compared to the consensus estimate of $1.02 million. Equities analysts anticipate that Dyadic International Inc. will post -0.15 earnings per share for the current year.

Hedge Funds Weigh In On Dyadic International

A hedge fund recently bought a new position in Dyadic International stock. BlackRock Inc. purchased a new stake in Dyadic International Inc. (NASDAQ:DYAI – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 197,749 shares of the biotechnology company’s stock, valued at approximately $177,000. BlackRock Inc. owned 0.54% of Dyadic International at the end of the most recent quarter. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Company Profile

(Get Free Report)

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.